Journal of Nanoparticle Research

, 15:1929 | Cite as

A facile drug delivery system preparation through the interaction between drug and iron ion of transferrin

  • Lin Zhou
  • Jihua Liu
  • Shaohua Wei
  • Xuefeng Ge
  • Jiahong Zhou
  • Boyang Yu
  • Jian Shen
Research Paper


Many anticancer drugs have the capability to form stable complex with metal ions. Based on such property, a simple method to combine these drugs with transferrin, through the interaction between drug and Fe ion of transferrin, to improve their anticancer activity, is proposed. To demonstrate this technique, the complex of photosensitive anticancer drug hypocrellin A and transferrin was prepared by such facile method. The results indicated that the complex of hypocrellin A and transferrin can stabilize in aqueous solution. In vitro studies have demonstrated the superior cancer cell uptake ability of hypocrellin A–transferrin complex to the free hypocrellin A. Significant damage to such drug-impregnated tumor cells was observed upon irradiation and the cancer cells killing ability of hypocrellin A–transferrin was stronger than the free hypocrellin A within a certain range of concentrations. The above results demonstrated the validity and potential of our proposed strategy to prepare the drug delivery system of this type of anti-cancer drugs and transferrin.


Transferrin Hypocrellin A Iron Cancer Drug delivery 



This research was financially supported by the National Natural Science Foundation of China (21201102), the Natural Science Foundation of Jiangsu Higher Education Institutions of China (No.12KJB150015 and 10KJB150008), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), One Hundred Talents Project Program of Nanjing Normal University, the Scientific Research Foundation of Nanjing Normal University (No. 2011103XG0249), and the Open Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (No. SKLNMKF201223).


  1. Accardi L, Di Bonito P (2010) Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem 17(17):1730–1755CrossRefGoogle Scholar
  2. Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin EV (2012) Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett 326(1):8–16CrossRefGoogle Scholar
  3. Bareford LA, Swaan PW (2007) Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59(8):748–758CrossRefGoogle Scholar
  4. Barreiro E, Casas JS, Couce MD, Sanchez A, Sanchez-Gonzalez A, Sordo J, Varela JM, Lopez EMV (2010) Dinuclear triphenylphosphinegold(I) sulfanylcarboxylates: synthesis, structure and cytotoxic activity against cancer cell lines. J Inorg Biochem 104(5):551–559CrossRefGoogle Scholar
  5. Bozec A, Fischel JL, Milano G (2006) Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol 18(4):330–334CrossRefGoogle Scholar
  6. Cao J, Liu Y, Jia L, Zhou HM, Kong Y, Yang G, Jiang LP, Li QJ, Zhong LF (2007) Curcurnin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radical Biol Med 43(6):968–975CrossRefGoogle Scholar
  7. Cavicchioli M, Massabni AC, Heinrich TA, Costa-Neto CM, Abrao EP, Fonseca BAL, Castellano EE, Corbi PP, Lustri WR, Leite CQF (2010) Pt(II) and Ag(I) complexes with acesulfame: crystal structure and a study of their antitumoral, antimicrobial and antiviral activities. J Inorg Biochem 104(5):533–540CrossRefGoogle Scholar
  8. Chen JN, Huang YW, Liu GS, Afrasiabi Z, Sinn E, Padhye S, Ma Y (2004) The cytotoxicity and mechanisms of 1,2-naphtoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol Appl Pharmacol 197(1):40–48CrossRefGoogle Scholar
  9. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Inv Drugs 11(6):755–768CrossRefGoogle Scholar
  10. Dai N, Guo J, Teo YN, Kool ET (2011) Protease probes built from DNA: multispectral fluorescent DNA-peptide conjugates as caspase chemosensors. Angew Chem Int Ed 50(22):5105–5109CrossRefGoogle Scholar
  11. Das S, Bhattacharya A, Mandal PC, Rath MC, Mukherjee T (2002) One-electron reduction of 1,2-dihydroxy-9, 10-anthraquinone and some of its transition metal complexes in aqueous solution and in aqueous isopropanol-acetone-mixed solvent: a steady-state and pulse radiolysis study. Radiat Phys Chem 65(1):93–100CrossRefGoogle Scholar
  12. Das M, Mohanty C, Sahoo SK (2009) Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 6(3):285–304CrossRefGoogle Scholar
  13. de Ilarduya CT, Duzgunes N (2000) Efficient gene transfer by transferrin lipoplexes in the presence of serum. Biochim Biophys Acta Biomembr 1463(2):333–342CrossRefGoogle Scholar
  14. Du XL, Zhang TI, Yuan L, Zhao YY, Li RC, Wang K, Yan SC, Zhang L, Sun HZ, Qian ZM (2002) Complexation of ytterbium to human transferrin and its uptake by K562 cells. Eur J Biochem 269(24):6082–6090CrossRefGoogle Scholar
  15. Du HY, Xiang JF, Zhang YZ, Tang YL (2007) A spectroscopic and molecular modeling of sinomenine binding to transferrin. Bioorg Med Chem Lett 17(6):1701–1704CrossRefGoogle Scholar
  16. Du HY, Xiang JF, Zhang YZ, Tang YL, Xu GZ (2008) Binding of V–IV to human transferrin: Potential relevance to anticancer activity of vanadocene dichloride. J Inorg Biochem 102(1):146–149CrossRefGoogle Scholar
  17. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J (2012) Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 20(10):813–830CrossRefGoogle Scholar
  18. Katsogiannou M, Peng L, Catapano CV, Rocchi P (2011) Active-targeted nanotherapy strategies for prostate cancer. Curr Cancer Drug Targets 11(9):954–965CrossRefGoogle Scholar
  19. Kim TH, Jo YG, Jiang HH, Lim SM, Youn YS, Lee S, Chen XY, Byun Y, Lee KC (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Controlled Release 162(2):422–428CrossRefGoogle Scholar
  20. Kostyuk VA, Potapovich AI, Vladykovskaya EN, Korkina LG, Afanas’ev IBA (2001) Influence of metal ions on flavonoid protection against asbestos-induced cell injury. Arch Biochem Biophys 385(1):129–137CrossRefGoogle Scholar
  21. Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Controlled Release 161(2):429–445CrossRefGoogle Scholar
  22. Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Controlled Release 161(2):175–187CrossRefGoogle Scholar
  23. Li HY, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22(3):225–250CrossRefGoogle Scholar
  24. Li HY, Sun HZ, Qian ZM (2002) The role of the transferrin–transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 23(5):206–209CrossRefGoogle Scholar
  25. Li SPY, Tang TSM, Yiu KSM, Lo KKW (2012) Cyclometalated iridium(III)-polyamine complexes with intense and long-lived multicolor phosphorescence: synthesis, crystal structure, photophysical behavior, cellular uptake, and transfection properties. Chem Eur J 18(42):13342–13354CrossRefGoogle Scholar
  26. Liang XL, Li XD, Yue XL, Dai ZF (2011) Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer. Angew Chem Int Ed 50(49):11622–11627CrossRefGoogle Scholar
  27. Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41(1):120–129CrossRefGoogle Scholar
  28. Luo LZ, Jin HW, Huang HQ (2012) Transferrin–cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity. J Proteomics 77:237–250CrossRefGoogle Scholar
  29. Ma F et al (2011) Spectroscopic studies on the interaction of elsinochrome A with myoglobin. Spectrosc Spect Anal 31(6):1601–1605Google Scholar
  30. Minko T, Dharap SS, Pakunlu RI, Wang Y (2004) Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 5(4):389–406CrossRefGoogle Scholar
  31. Nakase I, Lai H, Singh NP, Sasaki T (2008) Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 354(1–2):28–33CrossRefGoogle Scholar
  32. Nishiyama N, Morimoto Y, Jang WD, Kataoka K (2009) Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv Drug Deliv Rev 61(4):327–338CrossRefGoogle Scholar
  33. Ojima I (2008) Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxolds as warheads. Acc Chem Res 41(1):108–119CrossRefGoogle Scholar
  34. Park SY, Baik HJ, Oh YT, Oh KT, Youn YS, Lee ES (2011) A smart polysaccharide/drug conjugate for photodynamic therapy. Angew Chem Int Ed 50(7):1644–1647CrossRefGoogle Scholar
  35. Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds JV (2011) Nanodrug applications in photodynamic therapy. Photodiagn Photodyn Ther 8(1):14–29CrossRefGoogle Scholar
  36. Patri AK, Kukowska-Latallo JF, Baker JR (2005) Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57(15):2203–2214CrossRefGoogle Scholar
  37. Qian ZM, Li HY, Sun HZ, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54(4):561–587CrossRefGoogle Scholar
  38. Rajendiran V, Palaniandavar M, Periasamy VS, Akbarsha MA (2010) [Ru(phen)(2)(dppz)](2+) as an efficient optical probe for staining nuclear components. J Inorg Biochem 104(2):217–220CrossRefGoogle Scholar
  39. Rudnev AV, Foteeva LS, Kowol C, Berger R, Jakupec MA, Arion VB, Timerbaev AR, Keppler BK (2006) Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins. J Inorg Biochem 100(11):1819–1826CrossRefGoogle Scholar
  40. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98(10):1625–1633CrossRefGoogle Scholar
  41. Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updates 14(3):150–163CrossRefGoogle Scholar
  42. Sterz K, Mollmann L, Jacobs A, Baumert D, Wiese M (2009) Activators of P-glycoprotein: structure-activity relationships and investigation of their mode of action. ChemMedChem 4(11):1897–1911CrossRefGoogle Scholar
  43. Subbaram S, DiPersio CM (2011) Integrin alpha 3 beta 1 as a breast cancer target. Expert Opin Ther Tar 15(10):1197–1210CrossRefGoogle Scholar
  44. Tai WY, Mahato R, Cheng K (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Controlled Release 146(3):264–275CrossRefGoogle Scholar
  45. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y (2004) Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 277(1–2):39–61CrossRefGoogle Scholar
  46. Tang W, Xu H, Kopelman R, Philbert MA (2005) Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol 81(2):242–249CrossRefGoogle Scholar
  47. Tang J, Yang C, Zhou L, Ma F, Liu SC, Wei SH, Zhou JH, Zhou YH (2012) Studies on the binding behavior of prodigiosin with bovine hemoglobin by multi-spectroscopic techniques. Spectrochim Acta, Part A 96:461–467CrossRefGoogle Scholar
  48. Wei GC, Yan MM, Dong RH, Wang D, Zhou XZ, Chen JF, Hao JC (2012) Covalent modification of reduced graphene oxide by means of diazonium chemistry and use as a drug-delivery system. Chem Eur J 18(46):14708–14716CrossRefGoogle Scholar
  49. Widera A, Norouziyan F, Shen WC (2003) Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 55(11):1439–1466CrossRefGoogle Scholar
  50. Yan F, Kopelman R (2003) The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem Photobiol 78(6):587–591CrossRefGoogle Scholar
  51. Yang PH, Sun XS, Chiu JF, Sun HZ, He QY (2005) Transferrin-mediated gold nanoparticle cellular uptake. Bioconjugate Chem 16(3):494–496CrossRefGoogle Scholar
  52. Yang C, Ma F, Tang J, Han LN, Wei SH, Zhou L, Zhou JH, Shen J, Wang F (2012) Synthesis of vanadyl–hypocrellin A complex and its photodynamic properties research. Bioorg Med Chem Lett 22(15):5003–5007CrossRefGoogle Scholar
  53. Yong KT, Qian J, Roy I, Lee HH, Bergey EJ, Tramposch KM, He SL, Swihart MT, Maitra A, Prasad PN (2007) Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano Lett 7(3):761–765CrossRefGoogle Scholar
  54. Yu CL, Xu SJ, Chen S, Zhang MH, Shen T (2002) Investigation of photobleaching of hypocrellin B in non-polar organic solvent and in liposome suspension. J Photochem Photobiol, B 68(2–3):73–78CrossRefGoogle Scholar
  55. Zhao YY, Mandal R, Li XF (2005) Intact human holo-transferrin interaction with oxaliplatin. Rapid Commun Mass Spectrom 19(14):1956–1962CrossRefGoogle Scholar
  56. Zhou JH, Liu JH, Xia SQ, Wang XS, Zhang BW (2005) Effect of chelation to lanthanum ions on the photodynamic properties of hypocrellin A. J Phys Chem B 109(41):19529–19535CrossRefGoogle Scholar
  57. Zhou JH et al (2009) Spectroscopic studies on the interaction of hypocrellin A and hemoglobin. Spectrochim Acta, Part A 72(1):151–155CrossRefGoogle Scholar
  58. Zhou L, Liu JH, Ma F, Wei SH, Feng YY, Zhou JH, Yu BY, Shen J (2010a) Mitochondria-targeting photosensitizer-encapsulated amorphous nanocage as a bimodal reagent for drug delivery and biodiagnose in vitro. Biomed Microdev 12(4):655–663CrossRefGoogle Scholar
  59. Zhou L, Liu JH, Zhang J, Wei SH, Feng YY, Zhou JH, Yu BY, Shen J (2010b) A new sol-gel silica nanovehicle preparation for photodynamic therapy in vitro. Int J Pharm 386(1–2):131–137CrossRefGoogle Scholar
  60. Zhou L, Wang W, Tang J, Zhou JH, Jiang HJ, Shen J (2011) Graphene oxide noncovalent photosensitizer and its anticancer activity in vitro. Chem Eur J 17(43):12084–12091CrossRefGoogle Scholar
  61. Zhou L, Jiang HJ, Wei SH, Ge XF, Zhou JH, Shen J (2012a) High-efficiency loading of hypocrellin B on graphene oxide for photodynamic therapy. Carbon 50(15):5594–5604CrossRefGoogle Scholar
  62. Zhou L, Wei SH, Ge XF, Zhou JH, Yu BY, Shen J (2012b) External heavy-atomic construction of photosensitizer nanoparticles for enhanced in vitro photodynamic therapy of cancer. J Phys Chem B 116(42):12744–12749CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Jiangsu Key Laboratory Biofunctional Materials, Key Laboratory of Applied Photochemistry, Analysis and Testing Center, College of Chemistry and Materials ScienceNanjing Normal UniversityNanjingPeople’s Republic of China
  2. 2.Department of Complex Prescription of TCMChina Pharmaceutical UniversityNanjingPeople’s Republic of China

Personalised recommendations